In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
In making a selection of cellular tools and animal models for generating screening assays in the search for new drugs, one needs to take into consideration the practicality of their use in the drug discovery process. Conducting high-throughput primary screens using libraries of small molecules, close to 1 million members in size, requires the generation of large numbers of cells which are easily acquired, reliably enriched, and reproducibly responsive to standard positive controls. These cells need to be similar in form and function to their counterparts in human disease. In vitro assays that can be mechanized by using robots can therefore save time and costs. In selecting in vivo models, consideration must be given to the species and strain of animal chosen, the appropriateness of the model to human disease, the extent of animal husbandry required during the in-life pharmacological assessment, the technical aspects of generating the model and harvesting the tissues for analyses, the cost of research tools in terms of time and money (demyelinating and remyelinating agents, amount of compound to be generated), and the length of time required for drug testing in the model. A consideration of the translational aspects of the in vivo model compared to those used in the clinic is also important. These themes will be developed with examples for drug discovery in the field of CNS demyelination and repair, specifically as it pertains to multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345 · cited 4×
“Mason et al (2000) solved the problem of chronic IGF-1 delivery by creating the cuprizone model in IGF-1 + / + transgenic mice, whereas Barres et al, (1992) delivered PDGF on the CNS side of the BBB by implanting a hybridoma cell line secreting the neurotrophic factor.”
BackgroundInfluentialMatsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984 · cited 3×
“Chemically induced CNS lesions, such as those generated with cuprizone feeding or injection of EtBr or lysolecithin have several distinct advantages: (1) dissociation of the demyelination event from the complexities introduced into the tissue pathology by chronic inflammatory cells and their soluble mediators, (2) rep…”
BackgroundAstrocytes promote myelination in response to electrical impulses
Ishibashi, T., Dakin, K. A., Stevens, B., Lee, P. R., Kozlov, S. V., Stewart, C. L., & Fields, R. D. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.006 · Cited by 689
Induction of myelination in the central nervous system by electrical activity
Demerens, C., Stankoff, B., Logak, M., Anglade, P., Allinquant, B., Couraud, F., Zalc, B., & Lubetzki, C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9887 · Cited by 678
Sim, F. J., Zhao, C., Penderis, J., & Franklin, R. J. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02451.2002 · Cited by 625
Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐. (1993) · Annals of Neurology · doi:10.1002/ana.410330203 · Cited by 574 · cited 1×
“…has been well documented that these cells are activated by the CNS pathology in MS to migrate to the lesion sites and attempt to repair the damage by differentiating and remyelinating naked axons (Prineas and Connell, 1979; Prineas et al, 1984, 1989, 1993; Raine and Wu, 1993; Lassmann et al, 1997).”
BackgroundStevens (2002) · doi:10.1016/s0896-6273(02)01067-x · Cited by 543
Interleukin-1β Promotes Repair of the CNS
Mason, J. L., Suzuki, K., Chaplin, D. D., & Matsushima, G. K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07046.2001 · Cited by 502
Remyelination in multiple sclerosis
Prineas, J. W., & Connell, F. (1979) · Annals of Neurology · doi:10.1002/ana.410050105 · Cited by 454
Thorburne, S. K., & Juurlink, B. H. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67031014.x · Cited by 390
Kotter, M. R., Setzu, A., Sim, F. J., Van Rooijen, N., & Franklin, R. J. M. (2001) · Glia · doi:10.1002/glia.1085 · Cited by 385 · cited 4×
“Macrophage depletion, as with the other demyelinating models, impairs remyelination (Kotter et al, 2001) .”
BackgroundInfluentialCharles, P., Hernandez, M. P., Stankoff, B., Aigrot, M. S., Colin, C., Rougon, G., Zalc, B., & Lubetzki, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100076197 · Cited by 306 · cited 2×
“Myelination in these cultures systems is quantitated by counting of MBP-stained cells or the number of internodes/myelin segments, by toluidine blue staining (Wilson), and by validation of compact myelin using EM (Charles et al, 2000; Demerens et al, 1996; Stevens et al, 2002).”
MethodMultiple Sclerosis: Remyelination in Acute Lesions
Raine, C. S., & WU, E. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199305000-00003 · Cited by 285
Insulin-Like Growth Factor-1 Inhibits Mature Oligodendrocyte Apoptosis during Primary Demyelination
Mason, J. L., Ye, P., Suzuki, K., D'Ercole, A. J., & Matsushima, G. K. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05703.2000 · Cited by 237
Tiwari-Woodruff, S., Morales, L. B. J., Lee, R., & Voskuhl, R. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703783104 · Cited by 234
Mason, J. L., Toews, A., Hostettler, J. D., Morell, P., Suzuki, K., Goldman, J. E., & Matsushima, G. K. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63726-1 · Cited by 212
Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination
Franco-Pons, N., Torrente, M., Colomina, M. T., & Vilella, E. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.01.010 · Cited by 195 · cited 1×
“Franco-Pons et al (2007) have described the use of open field and rotorod tests in the cuprizone model, claiming functional deficits in the cuprizone-fed mice compared to normal fed controls.”
BackgroundRemyelination in multiple sclerosis
Lassmann, H., Brück, W., Lucchinetti, C., & Rodriguez, M. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300213 · Cited by 191 · cited 2×
“It has been well documented that these cells are activated by the CNS pathology in MS to migrate to the lesion sites and attempt to repair the damage by differentiating and remyelinating naked axons (Prineas and Connell, 1979; Prineas et al, 1984 Prineas et al, , 1989 Prineas et al, , 1993 Raine and Wu, 1993; Lassmann…”
Background17beta‐estradiol protects oligodendrocytes from cytotoxicity induced cell death
Takao, T., Flint, N., Lee, L., Ying, X., Merrill, J., & Chandross, K. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02370.x · Cited by 93 · cited 4×
“Double staining for immature (A2B5 + ) and mature (MBP + ) cells with ERa or ERb-specific antibodies demonstrated subcellular localization in the nucleus and cytoplasm by confocal microscopy; nuclear compartmentalization became more pronounced with cell maturation (Takao et al, 2004) .”
BackgroundMethodInfluentialSelf-citationNon‐human primate models of multiple sclerosis
Brok, H. P. M., Bauer, J., Jonker, M., Blezer, E., Amor, S., Bontrop, R. E., Laman, J. D., & ‘t Hart, B. A. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1830114.x · Cited by 85
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22 · cited 4×
“There are many published studies demonstrating the efficacy of growth factors or small molecules that induce expansion of precursors, recruit them to sites of pathology, and drive differentiation of endogenous oligodendrocyte progenitors (Okano et al, 2007; Stangel, 2004; Franklin, 2002; Webster, 1997; Oudega et al, 1…”
BackgroundMethodInfluential
Cited by
Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis
Bjelobaba, I., Begovic‐Kupresanin, V., Pekovic, S., & Lavrnja, I. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24224 · Cited by 181
“Similarly, optic neuritis is generated upon EtBr injection into the subarachnoid space (Merrill, 2009).”
BackgroundAnimal models of multiple sclerosis: From rodents to zebrafish
Burrows, D. J., McGown, A., Jain, S. A., De Felice, M., Ramesh, T. M., Sharrack, B., & Majid, A. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518805246 · Cited by 135
Experimental models of demyelination and remyelination
Torre-Fuentes, L., Moreno-Jiménez, L., Pytel, V., Matías-Guiu, J. A., Gómez-Pinedo, U., & Matías-Guiu, J. (2020) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.03.007 · Cited by 47
Models for Studying Myelination, Demyelination and Remyelination
Osorio-Querejeta, I., Sáenz-Cuesta, M., Muñoz-Culla, M., & Otaegui, D. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8442-1 · Cited by 38
Natarajan, C., Le, L. H. D., Gunasekaran, M., Tracey, K. J., Chernoff, D., & Levine, Y. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322577121 · Cited by 20
Metadata
- Authors
- Merrill, J. E.
- Venue
- Neuropsychopharmacology
- Published
- 2008-09-17
- Volume
- 34
- Issue
- 1
- Pages
- 55-73
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122830702
- Cited by
- 69
- References
- 21
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.